相关实验视频

Updated: May 3, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

在Graves的甲状腺功能障碍症中,在初始放射性治疗后的非完全缓解的预后诺莫格拉姆模型

Congcong Wang¹, Yutian Li², Guohua Qin¹

¹Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

Frontiers in endocrinology

|November 13, 2025

概括

对格雷夫斯甲状腺功能障碍的放射性治疗具有可变的成功率. 这项研究确定了像甲状腺质量和RAI吸收这样的关键预测因子,以创建一个预测非完全缓解和优化治疗的诺姆图.

科学领域:

内分泌学在内分泌学.
核医学就是核医学.
医疗信息学医疗信息学

背景情况:

放射性 (RAI) 治疗是格雷夫斯甲状腺功能障碍症 (GH) 的标准治疗方法.
RAI疗法具有可变的疗效,治愈率在50-80%之间.
非完全缓解 (NCR) 往往需要重新治疗,突出显示了对预测工具的需求.

研究的目的:

为了确定GH的RAI治疗后NCR的独立预测因子.
开发和验证用于个性化预测RAI治疗结果的预后性名录.

主要方法:

对285名接受初始RAI治疗的GH患者的回顾性分析.
数据分为培训 (n=199) 和验证 (n=86) 队列.
后勤回归用于识别预测因素;使用校准,ROC和DCA进行名ogram构建和验证.

主要成果:

甲状腺质量 (TM),24小时RAI吸收 (RAIU24h),有效半衰期 (Teff) 和 ΔFT3 是NCR的独立预测因素.
该名录显示了强大的区分性表现 (AUC培训=0.919,验证=0.901).
校准曲线显示出高保真度,DCA显示出显著的临床效用.

结论:

TM,RAIU24h,Teff和ΔFT3对于预测GH中的RAI疗效至关重要.
经过验证的名图允许对NCR进行精确的风险分层.
该工具可以帮助优化RAI活动处方,以提高缓解率.

关键词:

格雷夫斯甲状腺功能障碍症自由的三甲氨酸的变化命名图形模型命名图形模型不完全的缓解,不完全的缓解.放射性治疗是一种放射性治疗.

更多相关视频

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

相关概念视频

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Graves' Disease I: Introduction

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...